These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 19319484)

  • 21. Understanding and applying pharmacometric modelling and simulation in clinical practice and research.
    Standing JF
    Br J Clin Pharmacol; 2017 Feb; 83(2):247-254. PubMed ID: 27567102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficient pharmacokinetic modeling of complex clinical dosing regimens: the universal elementary dosing regimen and computer algorithm EDFAST.
    Sebaldt RJ; Kreeft JH
    J Pharm Sci; 1987 Feb; 76(2):93-100. PubMed ID: 3572761
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic-pharmacodynamic (PK-PD) modelling in non-steady-state studies and arterio-venous drug concentration differences.
    Gumbleton M; Oie S; Verotta D
    Br J Clin Pharmacol; 1994 Nov; 38(5):389-400. PubMed ID: 7893578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Application of the relationship between pharmacokinetics and pharmacodynamics in drug development and therapeutic equivalence: a PEARRL review.
    Loisios-Konstantinidis I; Paraiso RLM; Fotaki N; McAllister M; Cristofoletti R; Dressman J
    J Pharm Pharmacol; 2019 Apr; 71(4):699-723. PubMed ID: 30793317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics/pharmacodynamics model-supported early drug development.
    Chen B; Dong JQ; Pan WJ; Ruiz A
    Curr Pharm Biotechnol; 2012 Jun; 13(7):1360-75. PubMed ID: 22201585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Curvature-adjusted optimal design of sampling times for the inference of pharmacokinetic compartment models.
    Daimon T; Goto M
    Stat Med; 2007 Jun; 26(14):2799-812. PubMed ID: 17072822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of pharmacokinetic-pharmacodynamic model linearization on the accuracy of population information matrix and optimal design.
    Merlé Y; Tod M
    J Pharmacokinet Pharmacodyn; 2001 Aug; 28(4):363-88. PubMed ID: 11677932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of IPPSE, an alternative method for sequential population PKPD analysis.
    Lacroix BD; Friberg LE; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2012 Apr; 39(2):177-93. PubMed ID: 22270323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Weighted target interval stochastic control methods with global optimization and their applications in individualizing therapy.
    Ji S; Zeng Y; Wu P; Lee EJ
    J Pharmacokinet Pharmacodyn; 2007 Aug; 34(4):433-49. PubMed ID: 17497203
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.
    Gieschke R; Steimer JL
    Eur J Drug Metab Pharmacokinet; 2000; 25(1):49-58. PubMed ID: 11032091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A pharmacometric case study regarding the sensitivity of structural model parameter estimation to error in patient reported dosing times.
    Knights J; Rohatagi S
    J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):627-37. PubMed ID: 26209956
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology.
    Gabrielsson J; Green AR
    J Pharmacol Exp Ther; 2009 Dec; 331(3):767-74. PubMed ID: 19779129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-linear mixed-effects pharmacokinetic/pharmacodynamic modelling in NLME using differential equations.
    Tornøe CW; Agersø H; Jonsson EN; Madsen H; Nielsen HA
    Comput Methods Programs Biomed; 2004 Oct; 76(1):31-40. PubMed ID: 15313540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of dosage regimen in controlling indirect pharmacodynamic responses.
    Gobburu JV; Jusko WJ
    Adv Drug Deliv Rev; 2001 Mar; 46(1-3):45-57. PubMed ID: 11259832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interactive simulator for pharmacokinetics of repetitive drug dosing.
    Iben GA; Anderson JH
    Comput Programs Biomed; 1975 Mar; 4(3):113-20. PubMed ID: 1139911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The randomized concentration-controlled trial: an evaluation of its sample size efficiency.
    Sanathanan LP; Peck CC
    Control Clin Trials; 1991 Dec; 12(6):780-94. PubMed ID: 1665119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.
    Poulin P; Jones RD; Jones HM; Gibson CR; Rowland M; Chien JY; Ring BJ; Adkison KK; Ku MS; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Yates JW
    J Pharm Sci; 2011 Oct; 100(10):4127-57. PubMed ID: 21541937
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An effective approach for obtaining optimal sampling windows for population pharmacokinetic experiments.
    Ogungbenro K; Aarons L
    J Biopharm Stat; 2009; 19(1):174-89. PubMed ID: 19127474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using the time of maximum effect site concentration to combine pharmacokinetics and pharmacodynamics.
    Minto CF; Schnider TW; Gregg KM; Henthorn TK; Shafer SL
    Anesthesiology; 2003 Aug; 99(2):324-33. PubMed ID: 12883405
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimation and inference for a spline-enhanced population pharmacokinetic model.
    Li L; Brown MB; Lee KH; Gupta S
    Biometrics; 2002 Sep; 58(3):601-11. PubMed ID: 12229995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.